CTMXCytomX Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $76M
- 45% YoY
- Operating margin
- -29.3%
- 262% YoY
- EBITDA
- −$21M
- 180% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- −$16M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear8% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear0% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $37M | $53M | $101M | $138M | $76M | 45% |
| Operating income | −$116M | −$101M | −$6M | $25M | −$22M | 189% |
| Net income | −$116M | −$99M | −$569K | $32M | −$17M | 154% |
| Operating cash flow | −$119M | −$111M | −$56M | −$86M | −$76M | 12% |
| Capex | $2M | $2M | $840K | $310K | $220K | 29% |
| Stock-based comp | $13M | $13M | $9M | $8M | $6M | 18% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $5M | $11M | 266 | — |
| FY2024 | $2M | $1M | 64 | — |
| FY2023 | $3M | $519K | 97 | — |